ArticlePLoS neglected tropical diseases2018
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.
2 registry-linked trialsOpen access · goldAbstract read
In one paragraph
Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection)
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.Lancet (London, England) · 2020Trial
- Review
- The impact of single-cell genomics on the field of mycobacterial infection.Frontiers in microbiology · 2022Review
- Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.Methods in molecular biology (Clifton, N.J.) · 2022Article
- In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera.PLoS neglected tropical diseases · 2021Article
- Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance forActa pharmaceutica Sinica. B · 2021Article
- Identification of P218 as a potent inhibitor ofRSC medicinal chemistry · 2021Article
- Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer.Antimicrobial agents and chemotherapy · 2020Observational
- Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.Antimicrobial agents and chemotherapy · 2020Article
- Pharmacologic management ofExpert review of clinical pharmacology · 2020Review
- The Many Hosts of Mycobacteria 8 (MHM8): A conference report.Tuberculosis (Edinburgh, Scotland) · 2020Review
- Global Epidemiology of Buruli Ulcer, 2010-2017, and Analysis of 2014 WHO Programmatic Targets.Emerging infectious diseases · 2019Article
- In Vivo Imaging of BioluminescentThe American journal of tropical medicine and hygiene · 2019Article
- Mycolactone Toxin Membrane Permeation: Atomistic versus Coarse-Grained MARTINI Simulations.Biophysical journal · 2019Article
- Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.Antimicrobial agents and chemotherapy · 2019Article
- Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.Antimicrobial agents and chemotherapy · 2019Article
- High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.Antimicrobial agents and chemotherapy · 2019Article
- Treatment for Buruli ulcer: the long and winding road to antimicrobials-first.The Cochrane database of systematic reviews · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Paul J ConverseDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.ORCID 0000-0002-1256-7464
Deepak V AlmeidaDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.
Rokeya TasneenDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.
Vikram SainiDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.
Sandeep TyagiDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.
Nicole C AmmermanDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.
Si-Yang LiDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.
Nicole M AndersAnalytical Pharmacology Core, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Michelle A RudekAnalytical Pharmacology Core, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Jacques H GrossetDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.
Eric L NuermbergerDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, United States of America.
Johns Hopkins University · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MInstitute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MClosing the Gaps on Buruli Ulcer Diagnosis, Treatment, and PreventionR01AI113266 · NIAID · JOHNS HOPKINS UNIVERSITY · PI NUERMBERGER, ERIC L · 2016 to 2020
$4.4MAcquisition of a triple quadrupole mass spectrometer for small molecule analysisS10OD020091 · OD · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2015 to 2015
$314kNCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NIAID NIH HHS R01 AI113266NIH HHS S10 OD020091
Abstract
trial registrationClinicalTrials.gov NCT03474198, NCT01659437.
Indexed as
AnimalsAnti-Bacterial AgentsBuruli UlcerClofazimineDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationMiceMice, Inbred BALB CMycobacterium ulceransRifamycinsAnti-Bacterial AgentsClofazimineRifamycins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT01659437ClinicalTrials.gov
NCT03474198ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.